Induction of T helper1-driven antiviral T-cell lines for adoptive immunotherapy is determined by differential expression of IFN-γ and T-cell activation markers

Journal of Immunotherapy

Volumn 35, Issue 9, 2012, Pages 661-669

  Leibold, Josef ^a   Feucht, Judith ^a   Halder, Ameli ^a   Stevanovic, Stefan ^b   Kayser, Simone ^a   Handgretinger, Rupert ^a   Feuchtinger, Tobias ^a,c  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c German Center for Research in Infectious Disease (DZIF)   (Germany)

Author keywords

adenovirus; adoptive T cell transfer; cytomegalovirus

Indexed keywords

CD137 ANTIGEN; CYTOMEGALOVIRUS ANTIGEN PP65; GAMMA INTERFERON; CAPSID PROTEIN; CD40 LIGAND; CYTOMEGALOVIRUS MATRIX PROTEIN 65KDA; EPITOPE; HEXON CAPSID PROTEIN, ADENOVIRUS; MATRIX PROTEIN; PHOSPHOPROTEIN; VIRUS ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CELL EXPANSION; CELL ISOLATION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOMEGALOVIRUS; EX VIVO STUDY; HUMAN ADENOVIRUS; LYMPHOCYTE DIFFERENTIATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; TH1 CELL; VIRUS IMMUNITY; CD4 CD8 RATIO; CELL LINE; CYTOLOGY; CYTOTOXICITY; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PHENOTYPE; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION;

ANTIGENS, CD137; ANTIGENS, VIRAL; CAPSID PROTEINS; CD4-CD8 RATIO; CD40 LIGAND; CELL LINE; CYTOTOXICITY, IMMUNOLOGIC; EPITOPES, T-LYMPHOCYTE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; PHENOTYPE; PHOSPHOPROTEINS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES; TH1 CELLS; VIRAL MATRIX PROTEINS;

EID: 84868217145     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e318270e112     Document Type: Article

References (31)

1. Handgretinger R, Lang P, Schumm M, et al. Immunological aspects of haploidentical stem cell transplantation in children. Ann N Y Acad Sci. 2001;938:340-357; discussion 357-358.
2. Lang P, Handgretinger R, Niethammer D, et al. Transplantation of highly purified CD34+ progenitor cells from unrelated donors in pediatric leukemia. Blood. 2003;101: 1630-1636.
3. Mohty M, Jacot W, Faucher C, et al. Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen. Leukemia. 2003;17:2168-2177.
4. Bahceci E, Epperson D, Douek DC, et al. Early reconstitution of the T-cell repertoire after non-myeloablative peripheral blood stem cell transplantation is from post-thymic T-cell expansion and is unaffected by graft-versus-host disease or mixed chimaerism. Br J Haematol. 2003;122:934-943.
5. Lewin SR, Heller G, Zhang L, et al. Direct evidence for new T-cell generation by patients after either T-cell-depleted or unmodified allogeneic hematopoietic stem cell transplantations. Blood. 2002;100:2235-2242.
6. Ljungman P, Brand R, Einsele H, et al. Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. Blood. 2003;102:4255-4260.
7. Perruccio K, Tosti A, Burchielli E, et al. Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood. 2005;106:4397-4406.
8. Leen AM, Tripic T, Rooney CM. Challenges of T cell therapies for virus-associated diseases after hematopoietic stem cell transplantation. Expert Opin Biol Ther. 2010;10:337-351.
9. Riddell SR, Watanabe KS, Goodrich JM, et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science. 1992;257:238-241.
10. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995;333:1038-1044.
11. Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virusinduced lymphoma in allogeneic transplant recipients. Blood. 1998;92:1549-1555.
12. Peggs KS, Verfuerth S, Pizzey A, et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet. 2003;362:1375-1377.
13. Feuchtinger T, Richard C, Joachim S, et al. Clinical grade generation of hexon-specific T cells for adoptive T-cell transfer as a treatment of adenovirus infection after allogeneic stem cell transplantation. J Immunother. 2008;31:199-206.
14. Rauser G, Einsele H, Sinzger C, et al. Rapid generation of combined CMV-specific CD4+ and CD8+ T-cell lines for adoptive transfer into recipients of allogeneic stem cell transplants. Blood. 2004;103:3565-3572.
15. Feuchtinger T, Matthes-Martin S, Richard C, et al. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br J Haematol. 2006;134:64-76.
16. Feuchtinger T, Opherk K, Bethge WA, et al. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood. 2010;116:4360-4367.
17. Khanna N, Stuehler C, Conrad B, et al. Generation of a multipathogen-specific T-cell product for adoptive immunotherapy based on activation-dependent expression of CD154. Blood. 2011;118:1121-1131.
18. Zandvliet ML, van Liempt E, Jedema I, et al. Simultaneous isolation of CD8(+) and CD4(+) T cells specific for multiple viruses for broad antiviral immune reconstitution after allogeneic stem cell transplantation. J Immunother. 2011;34: 307-319.
19. Icheva V, Kayser S, Wolff D, et al. Adoptive transfer of EBNA1-specific T cells as a treatment of Epstein-Barr-Virus reactivation and lymphoproliferative disorders following allogeneic stem cell transplantation. J Clin Oncol. 2012. In press.
20. Thum E, Shao Z, Schwarz H. CD137, implications in immunity and potential for therapy. Front Biosci. 2009;14:4173-4188.
21. Wolfl M, Kuball J, Ho WY, et al. Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities. Blood. 2007;110:201-210.
22. Watanabe K, Suzuki S, Kamei M, et al. CD137-guided isolation and expansion of antigen-specific CD8 cells for potential use in adoptive immunotherapy. Int J Hematol. 2008; 88:311-320.
23. Frentsch M, Arbach O, Kirchhoff D, et al. Direct access to CD4+ T cells specific for defined antigens according to CD154 expression. Nat Med. 2005;11:1118-1124.
24. Feuchtinger T, Lang P, Hamprecht K, et al. Isolation and expansion of human adenovirus-specific CD4+ and CD8+ T cells according to IFN-gamma secretion for adjuvant immunotherapy. Exp Hematol. 2004;32:282-289.
25. Feuchtinger T, Lucke J, Hamprecht K, et al. Detection of adenovirus-specific T cells in children with adenovirus infection after allogeneic stem cell transplantation. Br J Haematol. 2005;128:503-509.
26. De Rosa SC, Brenchley JM, Roederer M. Beyond six colors: a new era in flow cytometry. Nat Med. 2003;9:112-117.
27. Leen AM, Myers GD, Sili U, et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med. 2006;12:1160-1166.
28. Wehler TC, Karg M, Distler E, et al. Rapid identification and sorting of viable virus-reactive CD4(+) and CD8(+) T cells based on antigen-triggered CD137 expression. J Immunol Methods. 2008;339:23-37.
29. Han S, Huang Y, Liang Y, et al. Phenotype and functional evaluation of ex vivo generated antigen-specific immune effector cells with potential for therapeutic applications. J Hematol Oncol. 2009;2:34-50.
30. Wolfl M, Kuball J, Eyrich M, et al. Use of CD137 to study the full repertoire of CD8+ T cells without the need to know epitope specificities. Cytometry A. 2008;73:1043-1049.
31. Klebanoff CA, Gattinoni L, Restifo NP. CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev. 2006;211:214-224.